Update shared on04 Sep 2025
Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility.
Analyst Commentary
- Disappointing Q2 report and weaker-than-expected operational performance.
- Lowered forward guidance and reduced visibility on near-term growth catalysts.
- Heightened concerns over limited upside drivers in the medium term.
- Adjustments in valuation to reflect more cautious growth and profitability expectations.
- Shift in analyst ratings towards more neutral stances due to revised risk/reward balance.
What's in the News
- Merck KGaA will hold an Analyst/Investor Day.
- The company revised 2025 group net sales guidance to EUR 20.5–21.7 billion and narrowed organic sales growth forecast to +2%–5%.
- The Center for Drug Evaluation (CDE) of China's NMPA accepted Merck KGaA's application for marketing authorization of pimicotinib for TGCT; the application, based on positive Phase 3 data, follows a Priority Review and Breakthrough Therapy Designation.
Valuation Changes
Summary of Valuation Changes for Merck KGaA
- The Consensus Analyst Price Target remained effectively unchanged, at €147.53.
- The Consensus Revenue Growth forecasts for Merck KGaA remained effectively unchanged, at 3.1% per annum.
- The Future P/E for Merck KGaA remained effectively unchanged, at 20.77x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.